Expert Interview
A look at TG Therapeutics ublituximab (Briumvi) for relapsing multiple sclerosis.
Ticker(s): TGTXInstitution: University of South Alabama Health
- Assistant Professor of Neurology and Director of the Neuroimmunology and MS Clinic at the University of South Alabama
- Treats approximately 750 patients with Multiple Sclerosis.
- Serves as principal investigator on several clinical trials and has delivered abstract presentations at several national meetings.
How do you interpret the sustained efficacy of ublituximab over six years in terms of relapse rates and MRI outcomes compared with your experience using other anti-CD20 therapies?
Added By: sara_adminHow do these long-term results influence your view of ublituximab relative to ocrelizumab or ofatumumab for relapsing MS?
Added By: sara_adminAre there specific patient profiles (e.g., high disease activity, adherence concerns, comorbidities) for whom these findings make ublituximab a particularly attractive option?
Added By: sara_adminWhat would be the role or potential clinical sequence for the use of fenebrutinib, and how would it relate to use/timing of briumvii by clinicians? (i.e., if fenebrutinib gains FDA approval in RRMS)
Added By: nomlastewCan you give us a sense or estimate of what the role SQ therapy will play in RRMS into the future? And to what degree (or even if) SQ will become the preferred or most common form of therapy delivery.
Added By: nomlastewAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
